Cancer Targeted Technology is a biotechnology company ommercializing innovative small molecules that bind pivotal enzyme targets in cancer. CTT has rationally designed and patented a targeting scaffold that recognizes the molecular target, Prostate-Specific Membrane Antigen (PSMA), with unparalleled binding characteristics, making it stand out from its competitors